Diskussion zu SANTHERA PHARMACEUTICALS HOLDING AG (Seite 1313)
eröffnet am 05.02.14 16:34:39 von
neuester Beitrag 25.04.24 15:30:16 von
neuester Beitrag 25.04.24 15:30:16 von
Beiträge: 14.080
ID: 1.191.124
ID: 1.191.124
Aufrufe heute: 6
Gesamt: 2.042.171
Gesamt: 2.042.171
Aktive User: 0
ISIN: CH1276028821 · WKN: A3EJMQ
9,5455
EUR
+0,08 %
+0,0080 EUR
Letzter Kurs 13:00:41 Lang & Schwarz
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 1,2100 | +21,00 | |
| 48,25 | +19,94 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,2600 | -14,25 | |
| 3,8500 | -14,45 | |
| 1,0011 | -15,88 | |
| 36,70 | -22,87 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 47.035.740 von olli60 am 23.05.14 14:42:06@Olli60: Der Unterschied ist, dass PTCT auf einem Cashberg von 245 Millionen USD sitzt und Santhera das Cash auszugehen droht - wobei sie nach den guten Daten natürlich neue Finanzierungen bekommen werden.
Adam Feuerstein von The Street.com sieht zudem gute Chancen, dass nun auch Prosensa ($DNA) die bedingte Zulassung erhält. Auch die steigen vorbörslich knapp 14%.
Wird immer spannender...
Adam Feuerstein von The Street.com sieht zudem gute Chancen, dass nun auch Prosensa ($DNA) die bedingte Zulassung erhält. Auch die steigen vorbörslich knapp 14%.
Wird immer spannender...
Antwort auf Beitrag Nr.: 47.035.686 von Braggo2 am 23.05.14 14:37:38Das zeigt aber auch, wie unterbewertet Santhera derzeit noch ist.
ahhh habs selbst gefunden 
wens interessiert :
http://www.finanzen.net/unternehmensprofil/Santhera_Pharmace…
wens interessiert :http://www.finanzen.net/unternehmensprofil/Santhera_Pharmace…
Glückwunsch zu diesem Fund, Biohero.
Wie schätzt Du die Meldung von PTC Therapeutics heute ein?
SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT +122.13% today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.
"We are very pleased with the outcome of the CHMP review of Translarna's marketing authorization application (MAA) and the level of engagement we experienced with CHMP members throughout the review process," said Robert J. Spiegel, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "We are grateful to the patients, families, advocacy groups and physicians who have supported PTC Therapeutics through many years of research and development of Translarna. It is important to note that this journey continues through the completion of our Phase 3 Translarna confirmatory trial in nmDMD (ACT DMD) which is a high priority for PTC and the DMD community."
Dr. Craig McDonald, Professor of Physical Medicine and Rehabilitation at the University of California, Davis, who developed and validated the 6-minute walk test as a primary clinical endpoint in Duchenne muscular dystrophy (DMD) stated, "This is a historic day for the DMD community. Translarna is the first treatment for the underlying cause of nonsense mutation DMD to receive a positive opinion from the CHMP. The Phase 2b clinical trial provided strong evidence that Translarna slows disease progression as measured by the 6-minute walk test. A clinically meaningful 31.3 meter benefit in 6-minute walk distance, relative to placebo, was achieved in 48 weeks of treatment in patients five years and older and this was supported by positive trends in multiple secondary efficacy endpoints. In addition, in the prespecified group of patients with less than a 350 meter baseline 6-minute walk distance, a 68 meter benefit was observed in patients treated with 40 mg/kg Translarna given daily, relative to placebo. A conditional approval by the European Commission based on this positive opinion would allow children with nmDMD in the European Union to gain access to Translarna while PTC Therapeutics completes its ongoing confirmatory trial."
---
Gleiche Indikation, bedingte Zulassung schon jetzt. Marke Cap ca. 1 Mrd. $ bei 30,07 Mio. Aktien ausstehend und vorbörslicher Kurs von 34 US-Dollar.
Wie groß ist das Gesamtmarktpotenzial für DMD? Haben da zwei Player Platz? Oder ist PTCT jetzt überbewertet. Danke für Deine Einschätzung.
Wie schätzt Du die Meldung von PTC Therapeutics heute ein?
SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT +122.13% today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.
"We are very pleased with the outcome of the CHMP review of Translarna's marketing authorization application (MAA) and the level of engagement we experienced with CHMP members throughout the review process," said Robert J. Spiegel, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "We are grateful to the patients, families, advocacy groups and physicians who have supported PTC Therapeutics through many years of research and development of Translarna. It is important to note that this journey continues through the completion of our Phase 3 Translarna confirmatory trial in nmDMD (ACT DMD) which is a high priority for PTC and the DMD community."
Dr. Craig McDonald, Professor of Physical Medicine and Rehabilitation at the University of California, Davis, who developed and validated the 6-minute walk test as a primary clinical endpoint in Duchenne muscular dystrophy (DMD) stated, "This is a historic day for the DMD community. Translarna is the first treatment for the underlying cause of nonsense mutation DMD to receive a positive opinion from the CHMP. The Phase 2b clinical trial provided strong evidence that Translarna slows disease progression as measured by the 6-minute walk test. A clinically meaningful 31.3 meter benefit in 6-minute walk distance, relative to placebo, was achieved in 48 weeks of treatment in patients five years and older and this was supported by positive trends in multiple secondary efficacy endpoints. In addition, in the prespecified group of patients with less than a 350 meter baseline 6-minute walk distance, a 68 meter benefit was observed in patients treated with 40 mg/kg Translarna given daily, relative to placebo. A conditional approval by the European Commission based on this positive opinion would allow children with nmDMD in the European Union to gain access to Translarna while PTC Therapeutics completes its ongoing confirmatory trial."
---
Gleiche Indikation, bedingte Zulassung schon jetzt. Marke Cap ca. 1 Mrd. $ bei 30,07 Mio. Aktien ausstehend und vorbörslicher Kurs von 34 US-Dollar.
Wie groß ist das Gesamtmarktpotenzial für DMD? Haben da zwei Player Platz? Oder ist PTCT jetzt überbewertet. Danke für Deine Einschätzung.
Demfall heute Abend PTCT kaufen??
Trading Spotlight
Soeben wurde ein DMD Konkurrenzprodukt in Europa zugelassen! Für die Aktie PTCT, dick im Plus in USA . Ist also vor Santhera am Markt. Eher negativ...
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_e…
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_e…
Soeben wurde ein DMD Konkurrenzprodukt in Europa zugelassen! Für dieAktie Ist also vor Santhera am Markt. Eher negativ...
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_e…
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_e…
Antwort auf Beitrag Nr.: 47.035.560 von illmatix am 23.05.14 14:25:26free float ca. 3,8 Mio
Gruß aaahhh
Gruß aaahhh
Antwort auf Beitrag Nr.: 47.035.606 von sorby am 23.05.14 14:30:11schick mir ne pn
Antwort auf Beitrag Nr.: 47.035.560 von illmatix am 23.05.14 14:25:26Die Aktionärsstruktur wird vom System gesperrt. Sie 2X oben.
Durchsuchen
